Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (0683-095 AMJ)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: October 14, 2008
Last updated: April 22, 2016
Last verified: April 2016